Clinical Trials Directory

Trials / Completed

CompletedNCT00215709

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer

A Pilot Study of Docetaxel on a Bi-Weekly Schedule in the Treatment of Elderly Men With Hormone-Refractory Prostate Cancer (HRPC)

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
17 (actual)
Sponsor
Geriatric Oncology Consortium · Academic / Other
Sex
Male
Age
65 Years
Healthy volunteers
Not accepted

Summary

This pilot study is designed to determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in older men with hormone refractory prostate cancer.

Detailed description

The information obtained from this trial will help determine the feasibility and safety of administering docetaxel at various dosing levels on a bi-weekly schedule in this patient population. If the data from this phase I trial are encouraging, a phase II trial will be conducted to further assess the efficacy of this dosing schedule.

Conditions

Interventions

TypeNameDescription
DRUGdocetaxel

Timeline

Start date
2004-07-01
Completion
2007-07-01
First posted
2005-09-22
Last updated
2007-11-19

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00215709. Inclusion in this directory is not an endorsement.

Bi-Weekly Administration of Docetaxel for Older Men With Hormone Refractory Prostate Cancer (NCT00215709) · Clinical Trials Directory